吡格列酮
肺动脉高压
曲格列酮
医学
肺动脉
受体
内科学
内分泌学
增殖细胞核抗原
细胞凋亡
过氧化物酶体增殖物激活受体
化学
免疫组织化学
生物化学
糖尿病
2型糖尿病
作者
Yasushi Matsuda,Yasushi Hoshikawa,Shingo Ameshima,Satoshi Suzuki,Yoshinori Okada,Toshiharu Tabata,Takafumi Sugawara,Yuuji Matsumura,Takashi Kondo
出处
期刊:PubMed
日期:2005-05-01
卷期号:43 (5): 283-8
被引量:56
摘要
Peroxisome proliferator-activated receptor gamma (PPARgamma) is a member of the nuclear hormone receptor superfamily, which regulates transcription of target genes in a ligand-dependent manner. Ligands for PPARgamma have been shown to attenuate proliferation of vascular smooth muscle cells, and to induce apoptosis in several cell lines in vitro. Since monocrotaline (MCT)-induced pulmonary hypertension in rats is characterized by proliferation of pulmonary vascular smooth muscle cells, we hypothesized that PPARgamma ligands may reduce MCT-induced pulmonary hypertension. To test this hypothesis, we treated MCT-injected rats with pioglitazone and troglitazone, synthetic ligands for PPARgamma, for three weeks and measured pulmonary artery pressure and pulmonary vessel wall thickness. TdT-mediated dUTP-biotin nick end labeling (TUNEL) and immunostaining for proliferating cell nuclear antigen (PCNA) were utilized to assess apoptosis and cell proliferation in the pulmonary arterial walls of pioglitazone-treated rats. MCT with pioglitazone or troglitazone treatment significantly reduced pulmonary hypertension and wall thickening of the pulmonary arteries. TUNEL-positive apoptotic cells were not seen in the pulmonary arterial walls of either MCT-injected or control rats with or without pioglitazone. PCNA-positive cells were only seen in the thickened pulmonary arterial walls of MCT rats, but not in the pulmonary arterial walls of controls and of pioglitazone-treated MCT rats. We conclude that PPARgamma ligands reduce MCT-induced pulmonary hypertension and pulmonary vascular wall thickening in rats. Inhibition of MCT-induced cell proliferation in the pulmonary arterial walls may account for this effect
科研通智能强力驱动
Strongly Powered by AbleSci AI